News
03-31-2010, 06:00 AM
Celsion Corporation announced today that after reviewing safety data from the 40mg/m2 cohort, the DIGNITY Study Drug Safety Monitoring Board (DSMB) has recommended that Celsion continue to enroll patients in the trial and that new patients be treated at a ThermoDox® dose of 50mg/m2.
More... (http://www.news-medical.net/news/20100331/DSMB-for-DIGNITY-trial-recommends-Celsion-continue-enrollment.aspx)
More... (http://www.news-medical.net/news/20100331/DSMB-for-DIGNITY-trial-recommends-Celsion-continue-enrollment.aspx)